SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-033764
Filing Date
2022-06-21
Accepted
2022-06-21 08:59:08
Documents
39
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_rasnatherap.htm   iXBRL 10-Q 405232
2 CERTIFICATION f10q0322ex31-1_rasnatherap.htm EX-31.1 9535
3 CERTIFICATION f10q0322ex32-1_rasnatherap.htm EX-32.1 3370
  Complete submission text file 0001213900-22-033764.txt   2253068

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20220331.xsd EX-101.SCH 29768
5 XBRL CALCULATION FILE rasp-20220331_cal.xml EX-101.CAL 21271
6 XBRL DEFINITION FILE rasp-20220331_def.xml EX-101.DEF 108214
7 XBRL LABEL FILE rasp-20220331_lab.xml EX-101.LAB 242685
8 XBRL PRESENTATION FILE rasp-20220331_pre.xml EX-101.PRE 114231
33 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_rasnatherap_htm.xml XML 191096
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 221026265
SIC: 2834 Pharmaceutical Preparations